FeesSafety
Pluang+

Dining out surges as Americans celebrate everyday moments and seek more experiences in 2027

Market News
04 Nov 2026, 16:00 WIB
PRNewsWire
View Source
Bullish
Dining out surges as Americans celebrate everyday moments and seek more experiences in 2027

OpenTable's 2027 Dining Trends Report reveals Americans are increasingly dining out to celebrate small wins and combine meals with entertainment, driving an 11% rise in reservations in 2026. Younger generations, especially Gen Z, are leading this trend by spending more on dining and seeking to become regulars at favorite spots. This shift highlights a broader change in dining habits, with consumers valuing experiences and meaningful connections over traditional celebrations. Restaurants can capitalize on this by offering varied experiences and building lasting guest relationships.

OpenTable's 2027 dining trends highlight evolving American dining habits. For readers following the Consumer Cyclical sector, here is Pluang's market snapshot as of Nov 04, 2026 21:12 WIB: Out of 134 stocks, 119 rose and 12 fell. MGM Resorts International led with a 4.16% gain at USD 32.31 and full buy interest on Pluang, contrasting with Amazon.com Inc's 4.12% rise to USD 261.02 but with 70% sell orders. Yum China Holdings Inc also gained 3.93% to USD 49.73, showing varied investor sentiment across the sector.

More News

Good Life Meds must stop unproven health and personalization claims for compounded Tirzepatide+ products.

Good Life Meds must stop unproven health and personalization claims for compounded Tirzepatide+ products.

The National Advertising Division (NAD) recommended that Good Life Meds discontinue claims about health benefits and personalization for its compounded Tirzepatide+ weight loss products after a challenge by Eli Lilly. NAD found that Good Life lacked ...

Market News
Bearish
24 minutes ago
Moleculin's Annamycin shows promising remission rates in AML trial, data to be presented at ASH 2026.

Moleculin's Annamycin shows promising remission rates in AML trial, data to be presented at ASH 2026.

Moleculin Biotech announced that interim results from its Phase 2/3 trial of Annamycin for relapsed or refractory acute myeloid leukemia (AML) will be presented at the 2026 ASH Annual Meeting. The trial showed remission rates of 43% and 36% in two An...

Company Fundamentals
Bullish
24 minutes ago
ANZ dental implants market to grow 5% CAGR, reaching $393M by 2033 driven by aging population and prosthetic demand

ANZ dental implants market to grow 5% CAGR, reaching $393M by 2033 driven by aging population and prosthetic demand

The Australia and New Zealand (ANZ) dental implants market, valued at $266 million in 2025, is projected to grow at a 5% CAGR to $393 million by 2033. Growth is driven by increasing demand for oral rehabilitation and prosthetic dentistry, especially ...

Market News
Bullish
24 minutes ago
New study shows Asgard's tech induces cancer-fighting structures in tumors, boosting therapy success across 7 cancer types.

New study shows Asgard's tech induces cancer-fighting structures in tumors, boosting therapy success across 7 cancer types.

Asgard Therapeutics published a study in Immunity demonstrating its technology can reprogram tumor cells into dendritic cells, inducing cancer-fighting tertiary lymphoid structures (imgTLSs) across seven tumor types. This tumor-agnostic approach led ...

Others
Bullish
24 minutes ago
Cap expands onchain credit marketplace to finance film production without tokenizing assets

Cap expands onchain credit marketplace to finance film production without tokenizing assets

Cap, an onchain credit marketplace, is expanding into film and media financing by providing funding for the upcoming film Wake. This deal uses advances against anticipated film production tax credits, showing how Cap's underwriting model supports spe...

Market News
Bullish
24 minutes ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App